• Je něco špatně v tomto záznamu ?

A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

E. Bachy, MJ. Maurer, TM. Habermann, B. Gelas-Dore, D. Maucort-Boulch, JA. Estell, E. Van den Neste, R. Bouabdallah, E. Gyan, AL. Feldman, J. Bargay, A. Delmer, SL. Slager, M. Gomes da Silva, O. Fitoussi, D. Belada, H. Maisonneuve, T....

. 2018 ; 132 (1) : 49-58. [pub] 20180417

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035295

Grantová podpora
P30 CA086862 NCI NIH HHS - United States
P50 CA097274 NCI NIH HHS - United States
U01 CA195568 NCI NIH HHS - United States

In follicular lymphoma (FL), no prognostic index has been built based solely on a cohort of patients treated with initial immunochemotherapy. There is currently a need to define parsimonious clinical models for trial stratification and to add on biomolecular factors. Here, we confirmed the validity of both the follicular lymphoma international prognostic index (FLIPI) and the FLIPI2 in the large prospective PRIMA trial cohort of 1135 patients treated with initial R-chemotherapy ± R maintenance. Furthermore, we developed a new prognostic tool comprising only 2 simple parameters (bone marrow involvement and β2-microglobulin [β2m]) to predict progression-free survival (PFS). The final simplified score, called the PRIMA-PI (PRIMA-prognostic index), comprised 3 risk categories: high (β2m > 3 mg/L), low (β2m ≤ 3 mg/L without bone marrow involvement), and intermediate (β2m ≤ 3 mg/L with bone marrow involvement). Five-year PFS rates were 69%, 55%, and 37% in the low-, intermediate-, and high-risk groups, respectively (P < .0001). In addition, achieving event-free survival (EFS) or not at 24 months (EFS24) was a strong posttreatment prognostic parameter for subsequent overall survival, and the PRIMA-PI was correlated with EFS24. The results were confirmed in a pooled external validation cohort of 479 patients from the FL2000 LYSA trial and the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. Five-year EFS in the validation cohort was 77%, 57%, and 44% in the PRIMA-PI low-, intermediate-, and high-risk groups, respectively (P < .0001). The PRIMA-PI is a novel and easy-to-compute prognostic index for patients initially treated with immunochemotherapy. This could serve as a basis for building more sophisticated and integrated biomolecular scores.

4th Department of Internal Medicine Hematology University Hospital Hradec Kralove Czech Republic Faculty of Medicine Charles University Prague Hradec Kralove Czech Republic

Centre Hospitalier de la Roche sur Yon Roche sur Yon France

Centre Hospitalier Pontchaillou Rennes France

CHU de Reims and Université Reims Champagne Ardenne Reims France

Chulalongkorn University Bangkok Thailand

Deparment of Biostatistics Lysarc Lyon France

Department of Haematology Concord Repatriation General Hospital Concord Sydney NSW Australia Sydney Medical School University of Sydney Sydney NSW Australia

Department of Health Sciences Research Mayo Clinic Rochester MN

Department of Hematology Centre Hospitalier Universitaire de Tours Tours France

Department of Hematology Hospices Civils de Lyon and Université Claude Bernard Université de Lyon INSERM102 Centre National de la Recherche Scientifique 5286 Pierre Bénite France

Department of Internal Medicine University of Iowa College of Medicine Iowa City IA

Department of Laboratory Medicine and Pathology Mayo Clinic Rochester MN

Division of Hematology Mayo Clinic Rochester MN

Hematology Department Cliniques Universitaires UCL Saint Luc Brussels Belgium

Hospices Civils de Lyon Service de Biostatistique et Bioinformatique and Université Lyon 1 Lyon France CNRS Unité Mixte de Recherche 5558 Laboratoire de Biométrie et Biologie Evolutive Equipe Biostatistique Santé Villeurbanne France

Hospital Son Llàtzer Palma de Mallorca Spain

Institut Gustave Roussy Villejuif France

Institut Paoli Calmettes Marseille France

Peter MacCallum Cancer Centre and University of Melbourne Melbourne VIC Australia

Polyclinique Bordeaux Nord Aquitaine Bordeaux France

Portuguese Institute of Oncology Lisbon Portugal

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035295
003      
CZ-PrNML
005      
20200401144736.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1182/blood-2017-11-816405 $2 doi
035    __
$a (PubMed)29666118
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Bachy, Emmanuel $u Department of Hematology, Hospices Civils de Lyon and Université Claude Bernard, Université de Lyon, INSERM102, Centre National de la Recherche Scientifique (CNRS)5286, Pierre-Bénite, France.
245    12
$a A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy / $c E. Bachy, MJ. Maurer, TM. Habermann, B. Gelas-Dore, D. Maucort-Boulch, JA. Estell, E. Van den Neste, R. Bouabdallah, E. Gyan, AL. Feldman, J. Bargay, A. Delmer, SL. Slager, M. Gomes da Silva, O. Fitoussi, D. Belada, H. Maisonneuve, T. Intragumtornchai, SM. Ansell, T. Lamy, P. Dartigues, BK. Link, JF. Seymour, JR. Cerhan, G. Salles,
520    9_
$a In follicular lymphoma (FL), no prognostic index has been built based solely on a cohort of patients treated with initial immunochemotherapy. There is currently a need to define parsimonious clinical models for trial stratification and to add on biomolecular factors. Here, we confirmed the validity of both the follicular lymphoma international prognostic index (FLIPI) and the FLIPI2 in the large prospective PRIMA trial cohort of 1135 patients treated with initial R-chemotherapy ± R maintenance. Furthermore, we developed a new prognostic tool comprising only 2 simple parameters (bone marrow involvement and β2-microglobulin [β2m]) to predict progression-free survival (PFS). The final simplified score, called the PRIMA-PI (PRIMA-prognostic index), comprised 3 risk categories: high (β2m > 3 mg/L), low (β2m ≤ 3 mg/L without bone marrow involvement), and intermediate (β2m ≤ 3 mg/L with bone marrow involvement). Five-year PFS rates were 69%, 55%, and 37% in the low-, intermediate-, and high-risk groups, respectively (P < .0001). In addition, achieving event-free survival (EFS) or not at 24 months (EFS24) was a strong posttreatment prognostic parameter for subsequent overall survival, and the PRIMA-PI was correlated with EFS24. The results were confirmed in a pooled external validation cohort of 479 patients from the FL2000 LYSA trial and the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. Five-year EFS in the validation cohort was 77%, 57%, and 44% in the PRIMA-PI low-, intermediate-, and high-risk groups, respectively (P < .0001). The PRIMA-PI is a novel and easy-to-compute prognostic index for patients initially treated with immunochemotherapy. This could serve as a basis for building more sophisticated and integrated biomolecular scores.
650    _2
$a senioři $7 D000368
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x aplikace a dávkování $7 D000971
650    _2
$a kostní dřeň $x metabolismus $x patologie $7 D001853
650    _2
$a přežití po terapii bez příznaků nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    12
$a imunoterapie $7 D007167
650    12
$a folikulární lymfom $x metabolismus $x mortalita $x patologie $x terapie $7 D008224
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádorové proteiny $x metabolismus $7 D009363
650    _2
$a míra přežití $7 D015996
650    _2
$a beta-2-mikroglobulin $x metabolismus $7 D001613
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Maurer, Matthew J $u Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
700    1_
$a Habermann, Thomas M $u Division of Hematology, Mayo Clinic, Rochester, MN.
700    1_
$a Gelas-Dore, Bénédicte $u Deparment of Biostatistics, Lysarc, Lyon, France.
700    1_
$a Maucort-Boulch, Delphine $u Hospices Civils de Lyon, Service de Biostatistique et Bioinformatique & Université Lyon 1, Lyon, France. CNRS, Unité Mixte de Recherche 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbanne, France.
700    1_
$a Estell, Jane A $u Department of Haematology, Concord Repatriation General Hospital, Concord, Sydney, NSW, Australia. Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
700    1_
$a Van den Neste, Eric $u Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.
700    1_
$a Bouabdallah, Réda $u Institut Paoli Calmettes, Marseille, France.
700    1_
$a Gyan, Emmanuel $u Department of Hematology, Centre Hospitalier Universitaire (CHU) de Tours, Tours, France.
700    1_
$a Feldman, Andrew L $u Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.
700    1_
$a Bargay, Joan $u Hospital Son Llàtzer, Palma de Mallorca, Spain.
700    1_
$a Delmer, Alain $u CHU de Reims and Université Reims Champagne Ardenne, Reims, France.
700    1_
$a Slager, Susan L $u Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
700    1_
$a Gomes da Silva, Maria $u Portuguese Institute of Oncology, Lisbon, Portugal.
700    1_
$a Fitoussi, Olivier $u Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.
700    1_
$a Belada, David $u 4th Department of Internal Medicine-Hematology, University Hospital, Hradec Kralove, Czech Republic. Faculty of Medicine, Charles University in Prague, Hradec Kralove, Czech Republic.
700    1_
$a Maisonneuve, Hervé $u Centre Hospitalier de la Roche sur Yon, Roche sur Yon, France.
700    1_
$a Intragumtornchai, Tanin $u Chulalongkorn University, Bangkok, Thailand.
700    1_
$a Ansell, Stephen M. $7 xx0246294 $u Division of Hematology, Mayo Clinic, Rochester, MN.
700    1_
$a Lamy, Thierry $u Centre Hospitalier Pontchaillou, Rennes, France.
700    1_
$a Dartigues, Peggy $u Institut Gustave Roussy, Villejuif, France.
700    1_
$a Link, Brian K $u Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, IA; and.
700    1_
$a Seymour, John F $u Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.
700    1_
$a Cerhan, James R $u Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
700    1_
$a Salles, Gilles $u Department of Hematology, Hospices Civils de Lyon and Université Claude Bernard, Université de Lyon, INSERM102, Centre National de la Recherche Scientifique (CNRS)5286, Pierre-Bénite, France.
773    0_
$w MED00000807 $t Blood $x 1528-0020 $g Roč. 132, č. 1 (2018), s. 49-58
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29666118 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20200401145209 $b ABA008
999    __
$a ok $b bmc $g 1451955 $s 1073845
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 132 $c 1 $d 49-58 $e 20180417 $i 1528-0020 $m Blood $n Blood $x MED00000807
GRA    __
$a P30 CA086862 $p NCI NIH HHS $2 United States
GRA    __
$a P50 CA097274 $p NCI NIH HHS $2 United States
GRA    __
$a U01 CA195568 $p NCI NIH HHS $2 United States
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace